Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis

Hepatology

Volumn 67, Issue 4, 2018, Pages 1485-1498

  García Lezana, Teresa ^a   Raurell, Imma ^a,b   Bravo, Miren ^a,b   Torres Arauz, Manuel ^a   Salcedo, María Teresa ^c   Santiago, Alba ^a   Schoenenberger, Andreu ^a   Manichanh, Chaysavanh ^a,b   Genescà, Joan ^a,b   Martell, María ^a,b   Augustin, Salvador ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; FARNESOID X RECEPTOR; INSULIN; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; HIGH FAT/HIGH SUCROSE DIET; HISTOPATHOLOGY; INTESTINE FLORA; INTRAHEPATIC ENDOTHELIAL DYSFUNCTION; LIPID DIET; LIVER DYSFUNCTION; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; VASCULAR RESISTANCE; ANIMAL; COMPLICATION; DISEASE MODEL; INSULIN RESISTANCE; LIVER; MICROBIOLOGY; PATHOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT;

ANIMALS; DISEASE MODELS, ANIMAL; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HYPERTENSION, PORTAL; INSULIN RESISTANCE; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 85042155286     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29646     Document Type: Article

References (29)

1. Berzigotti A, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 2011;54:555-561.
2. Berzigotti A, Albillos A, Villanueva C, Genescá J, Ardevol A, Augustín S, et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study. Hepatology 2017;65:1293-1305.
3. Francque S, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, et al. Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis. Eur J Gastroenterol Hepatol 2010;22:1449-1457.
4. Mendes FD, Suzuki A, Sanderson SO, Lindor KD, Angulo P. Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:1028-1033.
5. Francque S, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, et al. Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension. Int J Obes 2011;35:270-278.
6. Francque S, Wamutu S, Chatterjee S, Van Marck E, Herman A, Ramon A, et al. Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model. Liver Int 2010;30:365-375.
7. Francque S, Laleman W, Verbeke L, Van Steenkiste C, Casteleyn C, Kwanten W, et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Lab Investig 2012;92:1428-1439.
8. Pasarín M, La Mura V, Gracia-Sancho J, García-Calderó H, Rodríguez-Vilarrupla A, García-Pagán JC, et al. Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. PLoS One 2012;7:e32785.
9. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014;146:1513-1524.
10. Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota–liver axis in hepatic disease. Hepatology 2014;59:328-339.
11. Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013;62:1787-1794.
12. De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology 2014;59:1738-1749.
13. Moghadamrad S, McCoy KD, Geuking MB, Sägesser H, Kirundi J, Macpherson AJ, et al. Attenuated portal hypertension in germ-free mice: function of bacterial flora on the development of mesenteric lymphatic and blood vessels. Hepatology 2015;61:1685-1695.
14. García-Lezana T, Martell M, Ezkurdia N, Torres-Arauz M, Salcedo MT, Genescà J, et al. A diet combining high fat and glucose-fructose syrup induces obesity, non-alcoholic steatohepatitis and portal hypertension in a new animal model [Abstract]. J Hepatol 2016;64(Suppl.):452-453.
15. Abraldes JG, Iwakiri Y, Loureiro-Silva M, Haq O, Sessa WC, Groszmann RJ. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol 2006;290:G980-G987.
16. Marrone G, Russo L, Rosado E, Hide D, García-Cardeña G, García-Pagán JC, et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial–stellate cell deactivation induced by statins. J Hepatol 2013;58:98-103.
17. Pasarín M, Abraldes JG, Rodríguez-Vilarrupla A, La Mura V, García-Pagán JC, Bosch J. Insulin resistance and liver microcirculation in a rat model of early NAFLD. J Hepatol. 2011;55:1095-1102.
18. Jegatheesan P, Beutheu S, Freese K, Waligora-Dupriet A-J, Nubret E, Butel M-J, et al. Preventive effects of citrulline on Western diet–induced non-alcoholic fatty liver disease in rats. Br J Nutr 2016;116:191-203.
19. Jiang C, Xie C, Li F, Zhang L, Nichols RG, Krausz KW, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 2015;125:386-402.
20. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012;143:913-916.
21. Delzenne NM, Cani PD, Everard A, Neyrinck AM, Bindels LB. Gut microorganisms as promising targets for the management of type 2 diabetes. Diabetologia 2015;58:2206-2217.
22. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-1131.
23. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013;341:1241214.
24. Duncan ER, Walker SJ, Ezzat VA, Wheatcroft SB, Li J-M, Shah AM, et al. Accelerated endothelial dysfunction in mild prediabetic insulin resistance: the early role of reactive oxygen species. AJP Endocrinol Metab 2007;293:E1311-E1319.
25. Duncan ER, Crossey PA, Walker S, Anilkumar N, Poston L, Douglas G, et al. Effect of endothelium-specific insulin resistance on endothelial function in vivo. Diabetes 2008;57:3307-3314.
26. La Mura V, Pasarín M, Meireles CZ, Miquel R, Rodríguez-Vilarrupla A, Hide D, et al. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology 2013;57:1172-1181.
27. Fang S, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 2015;21:159-165.
28. Gonzalez FJ, Jiang C, Bisson WH, Patterson AD. Inhibition of farnesoid X receptor signaling shows beneficial effects in human obesity. J Hepatol 2015;62:1234-1236.
29. Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2014;59:2286-2298.